Cytokinetics Statistics
Share Statistics
Cytokinetics has 118.01M shares outstanding. The number of shares has increased by 20% in one year.
| Shares Outstanding | 118.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.62% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 113.57M |
| Failed to Deliver (FTD) Shares | 10.68K |
| FTD / Avg. Volume | 0.89% |
Short Selling Information
The latest short interest is 15.69M, so 13.29% of the outstanding shares have been sold short.
| Short Interest | 15.69M |
| Short % of Shares Out | 13.29% |
| Short % of Float | 13.81% |
| Short Ratio (days to cover) | 16.41 |
Valuation Ratios
The PE ratio is -15.31 and the forward PE ratio is -10.42.
| PE Ratio | -15.31 |
| Forward PE | -10.42 |
| PS Ratio | 1070.22 |
| Forward PS | 74.5 |
| PB Ratio | -20.86 |
| P/FCF Ratio | -19.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Cytokinetics has an Enterprise Value (EV) of 8.70B.
| EV / Earnings | -16.53 |
| EV / Sales | 1155.53 |
| EV / EBITDA | -19.05 |
| EV / EBIT | -17.54 |
| EV / FCF | -20.93 |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of -1.64.
| Current Ratio | 6.12 |
| Quick Ratio | 6.12 |
| Debt / Equity | -1.64 |
| Total Debt / Capitalization | 255.14 |
| Cash Flow / Debt | -0.65 |
| Interest Coverage | -8.6 |
Financial Efficiency
Return on equity (ROE) is 1.36% and return on capital (ROIC) is -134.31%.
| Return on Equity (ROE) | 1.36% |
| Return on Assets (ROA) | -0.64% |
| Return on Capital (ROIC) | -134.31% |
| Revenue Per Employee | 17.80K |
| Profits Per Employee | -1.24M |
| Employee Count | 423 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 34.9% in the last 52 weeks. The beta is 0.78, so Cytokinetics's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | 34.9% |
| 50-Day Moving Average | 52.87 |
| 200-Day Moving Average | 57.67 |
| Relative Strength Index (RSI) | 44 |
| Average Volume (20 Days) | 1.20M |
Income Statement
In the last 12 months, Cytokinetics had revenue of $7.53M and earned -$526.24M in profits. Earnings per share was $-5.45.
| Revenue | 7.53M |
| Gross Profit | -322.59M |
| Operating Income | -496.20M |
| Net Income | -526.24M |
| EBITDA | -456.68M |
| EBIT | -496.20M |
| Earnings Per Share (EPS) | -5.45 |
Balance Sheet
The company has $113.02M in cash and $755.77M in debt, giving a net cash position of -$642.75M.
| Cash & Cash Equivalents | 113.02M |
| Total Debt | 755.77M |
| Net Cash | -642.75M |
| Retained Earnings | -2.11B |
| Total Assets | 1.44B |
| Working Capital | 908.79M |
Cash Flow
In the last 12 months, operating cash flow was -$414.33M and capital expenditures -$1.42M, giving a free cash flow of -$415.75M.
| Operating Cash Flow | -414.33M |
| Capital Expenditures | -1.42M |
| Free Cash Flow | -415.75M |
| FCF Per Share | -4.31 |
Margins
Gross margin is -4.28K%, with operating and profit margins of -6.59K% and -6.99K%.
| Gross Margin | -4.28K% |
| Operating Margin | -6.59K% |
| Pretax Margin | -6.99K% |
| Profit Margin | -6.99K% |
| EBITDA Margin | -6.06K% |
| EBIT Margin | -6.59K% |
| FCF Margin | -5.52K% |
Dividends & Yields
CYTK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.2% |
| FCF Yield | -7.24% |
Analyst Forecast
The average price target for CYTK is $80, which is 64.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $80 |
| Price Target Difference | 64.4% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Stock Splits
The last stock split was on Jun 25, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -0.44 |
| Piotroski F-Score | 3 |